Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Good morning, everybody. Looks like we are ready to get rolling. My name is Jon Wolleben, senior analyst here at JMP Securities.
I am very pleased to have Madrigal Pharmaceuticals joining us this morning. We have Chief Medical Officer, Becky Taub; and then also Chris Frates, Executive Director, Corporate Communications. So thanks for joining us this morning.
And then, Becky, I think most people may be familiar with Madrigal, I would hope so; they're sitting in the room. But maybe just tell us a little bit about maybe not just Madrigal but resmetirom, your lead drug for NASH.
Yeah. So first of all, Madrigal is focused on resmetirom, which is a thyroid hormone receptor beta agonist for the treatment of NASH and NASH being non-alcoholic steatohepatitis. And we are in Phase 3 clinical development.
So we have had one study called MAESTRO-NAFLD that read out earlier
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
